miRNA Panel for Cerebral Vasospasm Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective biomarker for predicting and diagnosing cerebral vasospasm following aneurysmal subarachnoid hemorrhage, leading to inadequate early medical management and increased risk of chronic neurological disabilities.
Innovation Solution
The method involves analyzing microRNA (miRNA) levels in biological samples, such as cerebrospinal fluid or plasma, to identify specific miRNAs that correlate with the risk of cerebral vasospasm, using a panel of miRNAs like let-7b-5p, miR-15b-5p, miR-17-5p, miR-19b-3p, miR-20a-5p, miR-24-3p, and miR-29a-3p, and calculating a risk score to determine elevated risk for vasospasm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no biomarker is used for prediction, then clinical management follows a wait and see approach, but this results in delayed treatment and increased risk of chronic neurological disabilities
Solution Approach 1:
The patent performs miRNA analysis in biological samples (CSF, plasma, or serum) collected from aSAH patients to identify specific miRNA expression patterns that predict CVS risk before clinical symptoms appear. This preliminary biomarker assessment enables early risk stratification and timely intervention during the critical 3-10 day window when CVS most commonly occurs, resolving the contradiction between reliable prediction and timely diagnosis.
2Measurement precision
If frequent neurologic monitoring is performed to detect CVS, then early detection is possible, but this increases clinical workload and resource requirements
Solution Approach 1:
The patent replaces complex mechanical and clinical monitoring systems with a biochemical assay approach. By measuring miRNA expression levels in readily obtainable biological samples using molecular biology techniques, the system achieves accurate CVS prediction without requiring frequent neurologic examinations, Doppler ultrasounds, or angiographic monitoring, thereby reducing clinical workload while maintaining detection accuracy.
3Object-affected harmful factors
If early preventive treatment is initiated based on accurate risk prediction, then chronic neurological injuries are reduced, but this requires effective biomarkers that currently do not exist
Solution Approach 1:
The patent uses miRNA expression profiles as intermediary biomarkers that bridge the gap between aSAH occurrence and CVS development. Specific miRNAs (including but not limited to miR-125b, miR-142-3p, miR-146a, miR-155, miR-21, miR-221, and miR-223) serve as molecular mediators that reflect the pathological processes leading to CVS, enabling early risk identification and preventing neurological injury before it occurs.
Data Source
AI summary
A treatment method for cerebral vasospasm involves determining amounts of let-7b-5p, miR-9-3p, miR-142-3p, miR-15b-5p, miR-17-5p, miR-19b-3p, miR-20a-5p, miR-24-3p, miR-29a-3p, miR-125b-5p, and miR-142-3p in a biological sample obtained from a subject following aneurysmal subarachnoid hemorrhage (aSAH) to identify the subject as having an elevated risk of cerebral vasospasm, and administering a treatment to the subject when the elevated risk of cerebral vasospasm is identified.